araag2/HINT huggingface dataset:
Clinical trial NCT01064414 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2, renal insufficiency
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: canagliflozin, placebo
SMILES: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with T2DM not on an AHA or on any AHA in monotherapy or combination therapy
             (including oral or non oral agents)

          -  Patients with reduced kidney function

        Exclusion Criteria:

          -  History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta
             cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy

          -  Have proliferative diabetic retinopathy for which treatment is planned during the
             course of the study

          -  Kidney disease that required treatment with immunosuppressive therapy, history of
             dialysis or kidney transplant, presence of nephrotic syndrome (eg, severe proteinuria
             with hypoalbuminemia and/or edema), or inflammatory kidney disease

          -  Receiving anti hypertensive or anti-hyperlipidemic therapy not on a stable regimen

          -  History of a severe hypoglycemic episode within 6 months before screening
Clinical trial NCT01024608 (phase 3, status: completed)
Conditions: seasonal allergic rhinitis, hay fever
ICD codes: J30.2
Drugs: beclomethasone dipropionate, placebo nasal aerosol
SMILES: [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed Consent

          -  Male or female subjects 12 years of age or older

          -  Documented history of season allergic rhinitis to mountain cedar pollen

          -  General good health

          -  Other criteria apply

        Exclusion Criteria:

          -  History of physical findings of nasal pathology (within 60 days prior to screening
             visit)

          -  Participation in any investigational drug study 30 days preceding screening visit

          -  History of respiratory infection/disorder with 14 days preceding screening visit

          -  Use of any prohibited concomitant medications

          -  Other criteria apply
Clinical trial NCT01010633 (phase 3, status: completed)
Conditions: inflammation, pain
ICD codes: H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: vehicle of loteprednol etabonate, loteprednol etabonate
SMILES: CC1=CC(O)=CC(C)=C1Cl, [H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects who are at least 18 years of age.

          -  Subjects who are candidates for routine, uncomplicated cataract surgery.

          -  Subjects who, in the Investigator's opinion, have potential postoperative pinholed
             Snellen visual acuity (VA) of at least 20/200 in the study eye.

        Exclusion Criteria:

          -  Subjects who have known hypersensitivity or contraindication to the study drug or
             components.

          -  Subjects with a severe/serious ocular condition, or any other unstable medical
             condition, that in the investigator's opinion may preclude study treatment or
             follow-up.

          -  Subjects with elevated intraocular pressure (>/= 21mm Hg), uncontrolled glaucoma, or
             being treated for glaucoma in the study eye.

          -  Subjects who are monocular or have pinholed Snellen VA 20/200 or worse in the
             non-study eye.
Clinical trial NCT00676338 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: exenatide once weekly, metformin, sitagliptin, pioglitazone
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CSCC[C@H](N)C(O)=O, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  have type 2 diabetes and are treated with diet and exercise alone.

          -  at least 18 years of age.

          -  HbA1c between 7.1% and 11.0%, inclusive.

          -  Body mass index (BMI) of 23 kg/m2 to 45 kg/m2, inclusive.

          -  Have a history of stable body weight (not varying by >5% for at least 3 months prior
             to screening).

        Exclusion Criteria:

          -  Have history of cardiac disease or presence of active cardiac disease within the year
             prior to inclusion in the study including myocardial infarction, clinically
             significant arrhythmia, unstable angina, moderate to severe congestive heart failure,
             coronary artery bypass surgery, or angioplasty

          -  Have a history of renal transplantation or are currently receiving renal dialysis

          -  Have active or untreated malignancy, or have been in remission from clinically
             significant malignancy (other than basal cell or squamous cell skin cancer, in situ
             carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.

          -  Have history of severe GI disorder (e.g., gastroparesis)

          -  Have a history of acute or chronic pancreatitis.

          -  Have active proliferative retinopathy.

          -  Have been treated with drugs that promote weight loss (e.g., Xenical®[orlistat],
             Meridia® [sibutramine], Acomplia® [rimonabant], Acutrim® [phenylpropanolamine], or
             similar over-the-counter medications) within 3 months of screening.

          -  Have been treated with any antidiabetic agent for more than 7 days within 3 months
             prior to screening.

          -  Have had an organ transplant.

          -  Have previously completed or discontinued study drug in this study, withdrawn from
             this study or any other study investigating exenatide once weekly.

          -  Have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of study entry.

          -  Are currently enrolled in any other clinical study.
Clinical trial NCT00383578 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin 100 mg qd, metformin 1500 mg daily
SMILES: OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCC[C@H]1C#N, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Age from 65 years to the upper age limit recommended by local prescribing information
             for metformin

          -  Drug naive patients with type 2 diabetes.

          -  Body mass index (BMI) in the range of 22-40 kg/m2.

          -  HbA1c in the range of 7 to 9% inclusive

          -  FPG <270 mg/dL (15 mmol/L)

        Exclusion Criteria:

          -  A history of type 1 diabetes

          -  Evidence of significant diabetic complications

          -  Treatment with insulin or any other oral antidiabetic agents

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00374907 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: saxagliptin, placebo, metformin (blinded), metformin (open-label)
SMILES: N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)C12CC3CC(CC(O)(C3)C1)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Drug naive

          -  Hemoglobin A1c (HbA1c) ≥6.0% and ≤8.0%

          -  Fasting C-peptide ≥1.0 ng/mL

          -  Body mass index ≤40 kg/m²

        Exclusion Criteria:

          -  Recent cardiac or cerebrovascular event

          -  Elevated serum creatinine
Clinical trial NCT01521559 (phase 3, status: completed)
Conditions: branch retinal vein occlusion
ICD codes: H34.8332, H34.8331, H34.8311, H34.8321, H34.8391, H34.8312, H34.8322
Drugs: intravitreal aflibercept injection (iai;eylea®;bay86-5321)
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

        The following inclusion criteria include, but are not limited to:

          1. Adults ≥ 18 years of age with foveal center-involved macular edema (ME) secondary to
             BRVO diagnosed within 12 months before the screening visit

          2. ETDRS BCVA: letter score of 73 to 24 (20/40 to 20/320) in the study eye at screening
             and at day 1

          3. Provide signed informed consent

        Exclusion Criteria:

        The following exclusion criteria include, but are not limited to:

          1. Current bilateral manifestation of BRVO

          2. Uncontrolled glaucoma defined as ≥ 25 mmHg on optimal medical regimen, or previous
             filtration surgery in either the study eye or the fellow eye

          3. Insufficient clearing of macular hemorrhage that would prevent the patient from
             receiving laser treatment safely on day 1 (patients that meet this criterion may be
             rescreened once the macular hemorrhage resolves)

          4. Uncontrolled diabetes mellitus (DM)

          5. Previous use of intraocular corticosteroids or anti-angiogenic drugs in the study eye

          6. Use of periocular corticosteroids in the study eye within 3 months before day 1

          7. Use of intraocular or periocular corticosteroids or anti-angiogenic drugs in the
             fellow eye within 3 months before day 1

          8. Previous administration of systemic anti-angiogenic medications

          9. Panretinal scatter photocoagulation, sector laser photocoagulation, or macular grid
             photocoagulation in the study eye
Clinical trial NCT01153217 (phase 3, status: completed)
Conditions: hiv
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: switch from tenofovir to abacavir
SMILES: NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1
Eligibility criteria:

        Inclusion Criteria:

          1. Adult patients (=/+18 years old) having a diagnosis of HIV-1 infection.

          2. Current HAART including tenofovir plus emtricitabine/lamivudine plus a PI, a NNRTI or
             raltegravir started at least 12 months before.

          3. T-score ≤-2 measured by DEXA (within the last 6 months).

          4. Maintained undetectable plasma HIV-1 RNA (VL < 50 copies/mL) for at least 12 months.

          5. Absence of suspected or documented resistance mutations in the RT associated to
             abacavir.

          6. Voluntary written informed consent.

        Exclusion Criteria:

          1. History of intolerance, toxicity or virological failure to abacavir.

          2. HLA B*5701 positive.

          3. Secondary osteoporosis/osteopenia (vitamin D or testosterone deficit, thyroid disease,
             …)

          4. Therapy with biphosphonates within the last 12 months.
Clinical trial NCT00492024 (phase 3, status: completed)
Conditions: sinusitis
ICD codes: J01.80, J01.90, J32.0, J32.1, J32.2, J32.3, J32.8
Drugs: moxifloxacin (avelox, bay12-8039), placebo
SMILES: [H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Subjects must meet all the following criteria at the time of enrollment:

          -  Age >/= 18 years

          -  Clinical diagnosis of acute bacterial sinusitis with signs and symptoms present for =
             7 days but < 28 days as defined by A), radiographic, and B) clinical criteria, as
             follows:

               -  Radiographic Criteria: The presence of one or more of the following on a
                  radiographic paranasal sinus film (Waters' view): - Evidence of air-fluid levels
                  - Opacification

               -  Clinical Criteria: The presence of two major symptoms, or the presence of at
                  least one major and one minor symptom as defined in the list below:

                    -  Major symptoms: - Purulent anterior or posterior nasal discharge -
                       Unilateral facial pain or malar tenderness

                    -  Minor symptoms: - Frontal headache - Fever (oral = 38.0°C/100.4°F, tympanic
                       = 38.5°C/101.2°F, axillary = 37.5°C/99.5°F) - Culture material obtained by
                       sinus puncture; the aspirated specimen sent for Gram stain, quantitative
                       culture and susceptibility testing prior to initiation of antimicrobial
                       therapy

        Exclusion Criteria:

        Subjects with one or more of the following criteria will not be eligible for this study:

          -  History of chronic sinusitis defined as greater than four weeks of continuous symptoms
             (subjects with recurrent acute sinusitis will be included)

          -  History of sinus surgery (antral sinus puncture is not considered as a surgery)

          -  Any symptoms that suggest the subject's current illness is allergic rhinitis (e.g.
             repetitive sneezing, itchy nose or eyes, provocation by an allergen) and not acute
             bacterial sinusitis

          -  Known bacteremia, meningitis or infection infiltrating the tissues neighboring the
             sinuses
Clinical trial NCT02860624 (phase 3, status: completed)
Conditions: gastroesophageal reflux disease
ICD codes: K21.9, K21.00, K21.01
Drugs: 10 mg ilaprazole, 40mg esomeprazole
SMILES: COC1=C(C)C(C[S+]([O-])C2=NC3=CC(=CC=C3N2)N2C=CC=C2)=NC=C1, COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Consenting patients will be eligible for enrollment if they:

          -  are 18-70 years of age,

          -  have at least one of the two symptoms, heartburn and reflux,

          -  have photographically documented erosive esophagitis confirmed by
             esophagogastroduodenoscopy(EGD), and graded according to the Los Angeles (LA)
             Classification (A-D), within 5 days before randomization to treatment. Female patients
             are required to be nonpregnant, nonlactating, postmenopausal, surgically sterilized,
             or using a medically acceptable form of birth control, as determined by the
             investigator. Women of child- bearing potential will receive a pregnancy test.

        Exclusion Criteria:

          -  Patients will be ineligible if they:

          -  have cancerous or peptic ulcers, Zollinger-Ellison syndrome, varices of esophagus or
             fundus of stomach

          -  have a known history of gastric acid suppression operation, esophageal operation or
             peptic operation other than simple closure of perforation,

          -  have severe complications, severe other diseases of digestive tract such as Crohn's
             disease and ulcerative colitis, and severe other systemic diseases,

          -  have taken proton pump inhibitors within the 5 days or for more than three consecutive
             days within the two weeks immediately preceding start of study drug,

          -  participated in a clinical trial with an investigational drug or device within the
             past three months,

          -  have hypersensitivity or idiosyncratic reaction to ilaprazole, esomeprazole or any
             other benzimidazole,

          -  have alcoholic intemperance, drug addiction or any other improper habits.
Clinical trial NCT00081458 (phase 3, status: completed)
Conditions: short bowel syndrome
ICD codes: D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0
Drugs: placebo, teduglutide 0.05 mg/kg/d, teduglutide 0.1 mg/kg/d
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women, aged 18 years of age or older at the time of signing the informed
             consent form (ICF)

          -  SBS as a result of major intestinal resection resulting in at least 12 months
             intravenous feeding

          -  Body weight must be less than 90 kg

          -  At baseline, subjects must require PN treatment to meet their caloric or electrolyte
             needs due to ongoing malabsorption at least 3 times weekly and to be on a stable PN
             regimen for 4 weeks before dosing

          -  Body mass index (BMI) 18 to 27 kg/m2

          -  Adequate hepatic and renal function

        Exclusion Criteria:

          -  History of cancer or clinically significant lymphoproliferative disease with fewer
             than 5 years documented disease-free state

          -  History of alcohol or drug abuse (within previous year)

          -  Participation in a clinical study within 30 days prior to signing the ICF, or
             concurrent participation in any clinical study

          -  Clinically significant laboratory abnormalities at the time of randomization

          -  Previous use of teduglutide (ALX-0600)

          -  Prior use of native GLP-2 within 3 months of screening visit

          -  Hospital admission within 1 month prior to screening visit

          -  Pregnant or lactating women

          -  Any condition or circumstance, which in the investigator's opinion would put the
             subject at any undue risk, prevent completion of the study, or interfere with analysis
             of the study results.

          -  Presence of excluded disease: Radiation enteritis, Scleroderma, Celiac disease,
             Refractory/Tropical sprue, Pseudo-obstruction, Active inflammatory bowel disease
             (IBD), Pre-malignant/malignant change in colonoscopy biopsy or polypectomy, Surgery
             scheduled within the time frame of the study, Human immunodeficiency virus (HIV)
             positive test, Immunological disorders, Possible allergies to teduglutide or its
             constituents, Significant, active, uncontrolled, untreated systemic diseases
Clinical trial NCT00646009 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: budesonide/formoterol, fluticasone/salmeterol, albuterol
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  At least 18 years of age

          -  Diagnosis of asthma and baseline lung function test results as determined by the
             protocol

          -  Required and received inhaled corticosteroids within timeframe and doses specified in
             the protocol

        Exclusion Criteria:

          -  Severe asthma or asthma that is markedly effected by seasonal factors

          -  Has required and received non-inhaled corticosteroids within the previous 4 weeks, has
             sensitivity to drugs specified in the protocol or requires treatment with
             beta-blockers
Clinical trial NCT01202188 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: indacaterol and glycopyrronium (qva149), glycopyrronium (nva237), indacaterol (qab149), tiotropium, placebo
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female adults aged ≥40 yrs

          -  Smoking history of at least 10 pack years

          -  Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for
             Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008)

          -  Post-bronchodilator FEV1 < 80% and ≥ 30% of the predicted normal value and
             post-bronchodilator FEV1/FVC (forced vital capacity) <70%

        Exclusion Criteria:

          -  Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1

          -  Patients with concomitant pulmonary disease

          -  Patients with a history of asthma

          -  Any patient with lung cancer or a history of lung cancer

          -  Patients with a history of certain cardiovascular co-morbid conditions

          -  Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency

          -  Patients in the active phase of a supervised pulmonary rehabilitation program

          -  Patients contraindicated for inhaled anticholinergic agents and β2 agonists

          -  Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00092859 (phase 3, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: mk0557
SMILES: FC1=C(C=CC=C1)N1C=CC(NC(=O)[C@H]2CC[C@@]3(CC2)OC(=O)C2=C3C=NC=C2)=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Obese men and nonpregnant women at least 18 years of age with a specific body mass
             index (height and weight ratio) required by the study

        Exclusion Criteria:

          -  Patients with uncontrolled high blood pressure and/or diabetes mellitus (high blood
             sugar)
Clinical trial NCT00562692 (phase 3, status: terminated)
Conditions: heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: nesiritide, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    recruitment very difficult. study drug expired so we have stopped the study.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Males and females

          2. Over 18 years of age

          3. Confirmed written informed consent.

          4. Acute decompensated heart failure based on physicians assessment and requiring
             treatment as per standard emergency department protocols for this condition.

          5. Requirement for intravenous therapy of HF, e.g. diuretic, vasodilator.

          6. COAD based on physician's assessment and requiring treatment as per standard emergency
             department protocols for this condition. Must have at least 2 of the following
             criteria:

               -  history of smoking > 20 pack years,

               -  prior history of PFTs within last 1 year consistent with COAD,

               -  history of chronic cough and sputum production,

               -  progressive dyspnea, episodes of acute bronchitis over at least 2 yrs

        Exclusion Criteria:

          1. Women lactating, pregnant or of childbearing potential not using 2 reliable
             contraceptive methods.

          2. Patients who had received an investigational new drug within the last 4 weeks.

          3. Patients with a history of a psychological illness or condition such as to interfere
             with the patient's ability to understand the requirements of the study.

          4. SBP <90mmHg

          5. Creatinine >0.25mmol/L

          6. Sp02 < 80% on supplemental oxygen or known cor pulmonale with TR